Table 1.
Clinicopathological features of enrolled patients at baseline (N = 32).
| Clinicopathological features | |
|---|---|
| Age (years) | 55.3 ± 14.4 |
| Gender | Male 0/Female 32 cases |
| Disease duration of RA (months) | 129.7 ± 140.5 |
| Stage of RA | Stage I: 6/Stage II: 16/Stage III: 4/Stage IV: 6 cases |
| Functional class of RA | Class1: 10/Class 2: 19/Class 3: 3/Class 4: 0 cases |
| DAS28-ESR/DAS28-CRP | 4.6 ± 1.2/3.8 ± 1.1 (31 cases) |
| SDAI/CDAI | 19.8 ± 11.0/18.7 ± 11.0 (31 cases) |
| IgG (mg/dl) | 1782 ± 551 (31 cases) |
| Autoantibodies (positivity) | |
| RF/Anti-CCP antibodies | 90.6% (29/32 cases)/78.6% (22/28 cases) |
| Anti-SS-A/SS-B antibodies | 80.0% (24/30 cases)/10.7% (3/28 cases) |
| Organ involvements (prevalence) | |
| Interstitial lung disease (ILD) | 12.5% (4/32 cases) |
| Others | 12.5% (4/32 cases, Kidney 2, AR 1, PBC 1 case) |
| Saxon's test (mg/2 min) | 2232 ± 1908 (29 cases) |
| Schirmer's test (mm/5 min) | 3.6 ± 4.6 (25 cases) |
| Greenspan grading in LSG | 1: 8/2: 4/3: 9/4: 8 (29 cases) |
| Corticosteroid (prevalence) | 46.9% (15/32 cases) |
| Mean dose (15 cases; mg/day) | PSL 5.2 ± 2.7 |
| MTX (prevalence) | 75.0% (24/32 cases) |
| Mean dose (24 cases) (mg/week) | 9.4 ± 4.0 |
| DMARDs other than MTX (prevalence) | 34.4% (11/32 cases) |
| Previous Biologics (prevalence) | 21.9% (Bio-switch, 7; Bio-naïve, 25 cases) |
| IFX | 5 cases |
| ETN | 3 cases |
| ADA | 2 cases |
| TCZ | 1 case |
| GLM | 0 case |
| CER | 0 case (including overlap) |
RA rheumatoid arthritis, DAS28 disease activity score, SDAI Simplified Disease Activity Index, CDAI Clinical Disease Activity Index, AR aortic regurgitation, PBC primary biliary cirrhosis, LSG labial salivary gland, MTX, methotrexate, DMARDs disease-modifying anti-rheumatic drugs, IFX infliximab, ETN etanercept, ADA adalimumab, TCZ tocilizumab, GLM golimumab, CER certolizumab